Longevity science has attracted more venture capital, more celebrity endorsement, and more credentialed scientific attention in the past decade than in all previous decades combined. The results have been, with a small number of genuine exceptions, a sustained disappointment relative to the hype.
The core problem is biological complexity. Aging is not a single mechanism with a single intervention point. It is the cumulative expression of dozens of interacting processes — telomere attrition, mitochondrial dysfunction, cellular senescence, epigenetic drift, proteostasis failure — each of which contributes to the overall trajectory and none of which operates independently of the others. Intervening in one pathway, which is what most drug candidates and many supplements target, tends to produce modest effects that do not translate into meaningful lifespan or healthspan extension in practice.
The animal model problem compounds this. Mice age differently from humans, respond differently to interventions, and have repeatedly validated compounds in laboratory settings that then failed entirely in human trials. The graveyard of longevity interventions that worked brilliantly in mice is large. Resveratrol is probably the most famous example, but it is far from the only one.
The lifestyle interventions that do robustly extend healthy life — regular exercise, caloric moderation, sleep quality, social connection, not smoking — are well documented, unglamorous, and not fundable. They do not require a product or a prescription. They are therefore chronically underemphasized relative to their actual effect size.
The science will eventually produce real breakthroughs. Senolytics, GLP-1 pathway effects on aging, and epigenetic reprogramming are areas where genuine progress is visible. But the timeline is longer than the funding cycles suggest, and the supplements being sold against this narrative are mostly not the breakthroughs.